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Abstract
Background Lipoinjection is a promising treatment but
has some problems, such as unpredictability and a low rate
of graft survival due to partial necrosis.
Methods To overcome the problems with lipoinjection,
the authors developed a novel strategy known as cell-
assisted lipotransfer (CAL). In CAL, autologous adipose-
derived stem (stromal) cells (ASCs) are used in combina-
tion with lipoinjection. A stromal vascular fraction (SVF)
containing ASCs is freshly isolated from half of the aspi-
rated fat and recombined with the other half. This process
converts relatively ASC-poor aspirated fat to ASC-rich fat.
This report presents the ﬁndings for 40 patients who
underwent CAL for cosmetic breast augmentation.
Results Final breast volume showed augmentation by 100
to 200 ml after a mean fat amount of 270 ml was injected.
Postoperative atrophy of injected fat was minimal and did
not change substantially after 2 months. Cyst formation or
microcalciﬁcation was detected in four patients. Almost all
the patients were satisﬁed with the soft and natural-
appearing augmentation.
Conclusions The preliminary results suggest that CAL is
effective and safe for soft tissue augmentation and superior
to conventional lipoinjection. Additional study is necessary
to evaluate the efﬁcacy of this technique further.
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Autologous fat transplantation is one promising treatment
for facial rejuvenation and soft tissue augmentation
because it results in no incisional scar or complications
associated with foreign materials. However, certain prob-
lems remain, such as unpredictability and a low rate of
graft survival due to partial necrosis. Many innovations to
overcome these problems have been reported [1, 2, 4–6,
18] and reviewed previously [4, 14]. On the basis of these
reports, we tentatively concluded that we could harvest fat
with a 2.5-mm cannula or 18-gauge needle at a vacuum
lower than 700 mmHg and reinject it using an 18-gauge
needle without signiﬁcant adipocyte damage [14].
Lipoinjection can be used to treat facial changes asso-
ciated with aging and to correct various types of depressed
deformities such as hemifacial microsomia and pectus ex-
cavatum. It also has been used in breast augmentation by a
limited number of plastic surgeons [3], although the use
of autologous fat for breast augmentation has been
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DOI 10.1007/s00266-007-9019-4controversial. Consensus is lacking on whether lipoinjec-
tion is safe and appropriate because of microcalciﬁcations
that may cause confusion in the evaluation of mammo-
grams. Recently, autologous fat injection has been
reevaluated as a potential alternative to artiﬁcial implants
for breast augmentation [3, 15, 16, 19]. This reevaluation
may reﬂect recent advances in autologous fat transfer and
the radiologic detection of breast cancer.
To overcome the problems associated with autologous
fat transfer, we use a novel strategy known as cell-assisted
lipotransfer (CAL) (Fig. 1). Findings have shown that tis-
sue-speciﬁc progenitor cells in the adipose tissue have the
capacity to differentiate into various cell lineages [21].
Thus, the progenitors, currently known as adipose-derived
stem/stromal cells (ASCs), are expected to become a
valuable tool in a wide range of cell-based therapies.
The therapeutic concept of CAL was described in our
previous report on preclinical studies [9]. We found that
aspirated fat has approximately half the number of ASCs
found in excised whole fat. There are two main reasons for
this relative deﬁciency. First, a major portion of the ASCs
is located around large vessels and left in the donor site
after liposuction [9]. Second, a part of the ASCs is released
into the ﬂuid portion of liposuction aspirates [20]. The
relative deﬁciency of ASCs may induce postoperative
long-term atrophy of injected fat, as partially conﬁrmed in
animal studies [8, 9, 11].
With the CAL strategy, autologous ASCs are used to
enhance angiogenesis, to improve the survival rate of
grafts, and to reduce postoperative atrophy. In CAL, half
the volume of the aspirated fat is processed for isolation of
the stromal vascular fraction (SVF) containing ASCs.
During the isolation process, the other half of the aspirated
fat is prepared for grafting. Freshly isolated SVF, which we
characterized previously [20], is attached to the aspirated
fat, with the fat acting as a living scaffold before trans-
plantation. Finally, the SVF-supplemented fat is injected
into the target sites. Thus, ASC-poor fat is converted to
ASC-rich fat in the preparation process of the injectable
material.
In this report, we describe the preliminary results
experienced by patients who underwent CAL for cosmetic
breast augmentation. This is the ﬁrst report on the clinical
use of ASCs for cosmetic purposes.
Materials and Methods
Patients
From 2003 to 2007, we performed CAL for 70 patients: in
the breast for 60 patients (including 8 patients who had
breast reconstruction after mastectomy), in the face for 12
patients, and in the hip for 1 patient. For three patients,
CAL was performed at two sites. Informed consent was
obtained from all the patients. The study protocol con-
formed to the guidelines of the 1975 Declaration of
Helsinki and was approved by individual institutional
review boards.
In this study, 40 patients with healthy thoraxes and
breasts underwent CAL for purely cosmetic breast aug-
mentation. Patients undergoing breast reconstruction for
inborn anomaly or after mastectomy were not included. At
this writing, 19 of these 40 patients have been followed for
more than 6 months, and the maximum follow-up period
has been 42 months. All the patients were Japanese women
with a mean body mass index (BMI) of 19.1  1.9. Their
ages varied from 20 to 62 years (mean, 35.8  9.1). The
Fig. 1 Scheme of cell-assisted
lipotransfer. Relatively adipose-
derived stem/stromal cell
(ASC)-poor aspirated fat is
converted to ASC-rich fat by
supplementing ASCs isolated
from the other half of the
aspirated fat. The ASCs are
attached to the aspirated fat,
which is used as a scaffold in
this strategy
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123mean volume of injected fat was 268.1  47.6 ml on the
left side and 277.3  39.1 ml on the right side. The
demographic and surgical data for these patients are sum-
marized in Table 1.
Surgical Techniques
Before the procedure began, the liposuction site was
inﬁltrated with combined saline solution and diluted epi-
nephrine (0.001%). With the patient under general
anesthesia, adipose tissue was suctioned using a cannula
with a 2.5-mm inner diameter and a conventional lipo-
suction machine. Approximately half of the collected
liposuction aspirate was used for isolation of the SVF from
both the adipose and ﬂuid portions of the liposuction
aspirates, as described previously [20]. This cell processing
procedure required about 90 min. During the processing
period, the other half of the lipoaspirate was harvested as
graft material.
The adipose portion of the liposuction aspirates was
either washed several times and placed in an upright
position to obtain clear separation of ﬂuids and oil (groups
A and B) or centrifuged at 700 g for 3 min without washing
(group C), then put into a metal jar (500 ml), which was
placed in water with crushed ice. In groups A and C, the
fresh SVF isolated from both the adipose and ﬂuid portions
was added to the graft material. After gentle mixing and a
wait of 10 to 15 min for cell adherence to the aspirated fat,
the cell-supplemented fat was put into an injection syringe.
In Group B, the freshly isolated SVF was resuspended in
60 ml of saline, then diffusely injected into the whole
breast mounds separately (30 ml for each breast) immedi-
ately after conventional lipoinjection. There were 6
patients in group A, 2 patients in group B, and 32 patients
in group C.
For the injection syringe, a 10-ml LeVeen inﬂator
(Boston Scientiﬁc Corp., Boston, MA, USA) or our origi-
nal 20-ml syringe was used because each is a screw-type
syringe (with a threaded plunger), and the threaded con-
nections ﬁt both the connecting tube and the needle to
allow precise control during injection. To reduce the time
of the procedure, two syringes were used. While the one
syringe was being used for an injection, the other was being
ﬁlled with the graft material in preparation for the next
injection. An 18-gauge needle (150 mm long) was used for
lipoinjection and inserted subcutaneously at one of four
points indicated in Figs. 2A and B.
The operator took care to insert and place the needle
horizontally (parallel to the body) to avoid damaging the
pleura and causing a pneumothorax. The needle was
inserted in several layers and directions. It was continu-
ously and gradually retracted as the plunger was advanced.
This technique was used to obtain a diffuse distribution of
the graft material (Figs. 2 and 3). The grafts were injected
into the fatty layers on, around, and under the mammary
glands, and also into the pectoralis muscles.
Results
The transplantation of adipose tissue was successfully
performed in all cases, and the time of the injection process
ranged from 35 to 60 min for both breasts. Subcutaneous
bleeding, occasionally seen in some parts of the breasts,
resolved in 1 to 2 weeks.
Transplanted adipose tissue was gradually absorbed
during the ﬁrst 2 postoperative months (especially during
the ﬁrst month), and the breast volume showed a minimal
change thereafter, although skin tension sometimes less-
ened after 2 months. Three representative surgical sites are
shown in Figs. 4 to 9. The difference in breast circumfer-
ence (chest circumference at the nipple minus the chest
circumference at the inframammary fold) had increased in
all cases by 4 to 8 cm at 6 months, which corresponds to
two to three brassiere cup sizes. This circumference
increase appeared to correspond to the 100- to 200-ml
increase in the volume of each breast mound, which was
partially conﬁrmed by our preliminary evaluation using a
three-dimensional quantitative measurement system.
Compared with breast augmentation using implants of
the same size, augmentation with CAL showed a lower
height but a more natural contour of the breasts. All cases
but one (see later) showed natural softness of the breasts
Table 1 Patient data
No. of cases 40
Sex 40 F, 0 M
Age (years) 35.8  9.1
BMI 19.7  1.9
Surgical procedure
Group A 6
Group B 2
Group C 32
Site of liposuction
Thighs 25
Thighs and abdomen 13
Thighs and lower legs 2
Total volume of suctioned fat (ml) 1111.8  164.0
Volume of injection (ml)
Left 268.1  47.6
Right 277.3  39.1
Operation time (min) 257.1  39.1
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123without any palpable nodules at 6 months, and all the
patients were satisﬁed with the resulting texture, softness,
contour, and absence of foreign materials despite the lim-
ited size increase possible with autologous tissue—Cyst
formation (\12 mm) was detected by magnetic resonance
imaging (MRI) in two patients, and microcalciﬁcation was
detected by mammogram in two patients at 24 months. In
one of two patients in group B, ﬁbrous breast tissue and
ﬁbrosis on the sternum were observed by computed
tomography (CT) scan at 6 months, and the breasts were
found to be harder than in other cases.
Discussion
Modiﬁcations of lipoinjection techniques to improve the
survival rate for injected fat have been attempted. From
these, it is well accepted that adipose tissue should be
placed as small aliquots [3], preferably within an area 3
mm in diameter [1]. Because it takes a long time to perform
ideally diffuse distribution of suctioned fat [3], we have
used a disposable syringe with a threaded plunger and
connections, a very long needle (150 mm), and an assistant
to rotate the plunger. As a result, only 35 to 60 min are
required for injection in both breasts. These devices are
critical to performing large-volume lipoinjection safely and
precisely in a short time.
In addition, the harvesting, preserving, and reﬁning of
graft materials also are important, as repeatedly indicated
in the literature. We used a relatively large suction cannula,
centrifuged the aspirated fat in some cases, and kept it
cooled until transplantation. In this study, the clinical
results (increase in breast circumference) appeared to be
better in group C (using centrifuged fat) than in group A
(using noncentrifuged fat), although quantitative measure-
ment and statistical comparison were not done. In a
previous study, we found that centrifugation of aspirated
fat is substantially inﬂuential because centrifugation at
1,200 g decreases the fat volume by 30%, damaging 12%
of the adipocytes and 0% of the ASCs. This leads to the
concentration of cell numbers per volume of adipocytes
and ASCs by 25% and 43%, respectively [7].
In addition, centrifugation may be especially beneﬁcial
in our treatment because water content in the graft material
may disturb the adherence of ASCs to the adipose tissue
and interfere with differentiation into expected lineages.
Any ASCs ﬂoating in a solution, which is a nonphysiologic
environment, may migrate over distances, penetrate into
the lymphatic ﬂow, and differentiate unexpectedly. We
believe that such migration and altered cell differentiation
caused the development of ﬁbrotic tissue on the sternum of
one patient in group B. Thus, we conclude that centrifuged
fat combined with ASCs as cell pellets (group C procedure)
was best among the three methods used in this study.
Although small cystic formation and microcalciﬁcation
were detected in some cases, the microcalciﬁcation was
easily distinguished from that associated with breast can-
cer, and the overall cosmetic results were generally
satisfactory and encouraging. Almost all the patients were
Fig. 2 Schematic instruction of the injection method. (A) A small
amount of fat tissue is injected as small aliquots or as a thin string
with a long needle, using a syringe with a threaded plunger, while the
needle is continuously withdrawn. (B) The needle is inserted from
either one of two points on the areola margin or one of two points at
the inframammary fold in variable directions and planes to achieve a
diffuse distribution
Fig. 3 A clinical view of injection. The injection needle is rigidly
manipulated by an operator while an assistant rotates the plunger
according to the operator’s instruction. A high-pressure injection can
be performed using a disposable syringe with a threaded plunger. A
150-mm-long, 18-gauge needle is connected to the syringe with a
connecting tube threaded at both ends
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123satisﬁed with their enlarged and soft breasts with a natural
contour. Both CT scans and MRI showed that transplanted
fat tissue survived and formed a signiﬁcant thickness of the
fatty layer not only subcutaneously on and around the
mammary glands, but also between the mammary glands
and the pectoralis muscles. Breast volume stabilized 2 to 3
months after transplantation.
Maximum breast augmentation using the described
technique varied among the patients and appeared to be
100 to 200 ml. Although these volumes may be smaller
Fig. 4 Clinical views of a
patient in group A (patient 1).
Preoperative (left) and
postoperative (right) views at 24
months. A 22-year-old woman
underwent breast augmentation
using cell-assisted lipotransfer
(CAL) (290 ml in each breast),
with satisfactory results at 24
months. Her breast
circumference increased by 5
cm, and her augmented breast
mounds remained soft and
natural appearing without
injection scars or subcutaneous
indurations
Fig. 5 Radiologic views
showing the chest of patient 1.
(A) A preoperative computed
tomography (CT) image in the
horizontal plane of the nipples.
(B) A horizontal image 12
months after surgery. Note that
the adipose tissue is augmented
both subcutaneously and under
the mammary glands. (C)
Mammograms at 12 months
show no calciﬁcation or other
abnormal signs
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123than those achieved with large artiﬁcial implants, a deﬁnite
advantage is that patients need not be concerned about
postoperative complications induced by artiﬁcial implants
such as rupture, infection, capsular contracture, unnatural
contour, hardness, neurologic symptoms, and immune
response. Compared with our dozens of patients who
underwent conventional autologous lipoinjection to the
breasts, augmentation effects were apparently higher with
CAL. A 2- to 3-cm increase in breast circumference was
common with the conventional procedure, compared with
the 4- to 8-cm increase seen in this trial of CAL, although
the augmentation effect varied among patients. The mea-
surement system we recently devised may help to quantify
the difference in augmented volume in the future.
Adipose tissue contains not only adipogenic progenitor
cells, but also multipotent stem cells, which can
Fig. 6 Clinical views of a
patient in group C (patient 2).
Preoperative (top) and
postoperative (bottom) views at
12 months. A 32-year-old
woman underwent breast
augmentation with cell-assisted
lipotransfer (CAL) (280 ml in
each breast). Her breast
circumference difference
increased from 9 cm (baseline)
to 14.5 cm (at 12 months). The
breast mounds are soft and
natural appearing with no
visible injection scars
Fig. 7 Radiologic views
showing the chest of patient 2.
(A) A preoperative computed
tomography (CT) image in the
horizontal plane at the level of
the nipples. (B and C)
Horizontal images by magnetic
resonance imaging (MRI) 12
months after surgery: (B) T1-
image; (C) T2-image. The
adipose tissue is augmented
around and under the mammary
glands. A small cyst (\10 mm)
appears in the fatty layer under
the right mammary gland. (D)
Mammograms at 12 months
show no abnormal signs such as
calciﬁcations
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123differentiate into fat, bone, cartilage, and types of tissue
[21, 22]. Suctioned fat appears to lose a signiﬁcant
number of these precursors during liposuction and the
preparation processes as compared with nonsuctioned
adipose tissue [9]. This relative deﬁciency of precursors
may contribute to the low survival rate and long-term
atrophy of transplanted lipoaspirates. In CAL, the deﬁcit
of ASCs was compensated by supplementing ASCs. To
maximize the biologic function and avoid unexpected
behavior of ASCs, it seems important to ensure adher-
ence of supplemented ASCs to adipocytes or connective
tissue.
With this novel treatment, ASCs have four possible
roles, which were partly conﬁrmed in preclinical studies [8,
9, 11]. First, ASCs can differentiate into adipocytes and
contribute to the regeneration of adipose tissue. Second,
ASCs can differentiate into endothelial cells and also
probably into vascular mural cells [8, 10, 12], resulting in
the promotion of angiogenesis and graft survival. Third,
ASCs are known to release angiogenic growth factors in
response to hypoxia and other conditions [13], and these
factors inﬂuence surrounding host tissue. In their ﬁnal role,
which may be the most inﬂuential, ASCs survive as ori-
ginal ASCs [9]. In the adipose tissue, ASCs reside between
adipocytes or in the extracellular matrix, especially around
vessels, and contribute to the turnover of adipose tissue,
which is known to be very slow (2 years or more) [17].
However, adipose grafts probably turn over during the ﬁrst
2 to 3 months after transplantation because they experience
temporary ischemia followed by reperfusion injury. This
turnover, the replacement process of the adipose tissue, is
conducted by tissue-speciﬁc progenitor cells, which are
ASCs. The relative deﬁciency of ASCs in aspirated fat may
affect the replacement process and lead to postoperative
Fig. 8 Clinical views of a
patient in group C (patient 3).
Preoperative (top) and
postoperative (bottom) views at
24 months. A 30-year-old
woman underwent breast
augmentation with cell-assisted
lipotransfer (CAL) (310 ml in
each breast). Her breasts were
dramatically augmented with an
increase in breast circumference
difference by 8 cm at 24
months. The breast mounds
were soft with no subcutaneous
indurations. An original
inframammary fold on the left
breast is slightly visible, but
injection scars are not visible
Fig. 9 Radiologic views of
patient 3. (A) A preoperative
computed tomography (CT)
image in the horizontal plane at
the level of the nipples. Only a
very thin fatty layer is observed
around the mammary glands.
(B) A horizontal magnetic
resonance image (MRI) (T1
weighted) 24 months after
surgery. Transplanted adipose
tissues survived and formed
thick layers around and under
the mammary glands. (C)
Mammograms 24 months after
surgery show no abnormal signs
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123atrophy of grafted fat, which is known to occur commonly
during the ﬁrst 6 months after lipoinjection.
The freshly isolated SVF used in CAL contains not only
ASCs but also vascular endothelial cells, pericytes, blood
cells (both white and red), and other cells, as previously
described [20]. After transplantation, ASCs may interact
with other cells such as vascular endothelial cells, and
supplementation with the SVF may be superior to supple-
mentation with ASCs alone in this treatment. However,
further studies are needed to elucidate the synergistic
effects of ASCs with other cells contained in the graft.
In this preliminary study, satisfactory clinical results
were generally achieved without any major complications.
Thus, we can conclude that CAL is sufﬁciently safe for
continuation of the study, though controlled investigations
and accumulated long-term results are needed to elucidate
the overall safety and efﬁcacy of the treatment. A variety of
new innovations, including stem cell technology, may be
developed and may contribute to the improvement of
autologous tissue transplantation and regeneration. Further
improvements of the technique may cause autologous tis-
sue transfer to become the ﬁrst choice for breast
augmentation in the future.
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